Objective To explore the curative effect of trastuzumab combined with oxaliplatin+S-1(SOX)regimen on patients with advanced gastric cancer(AGC)and its influences on levels of serum tumor markers.Methods A total of 68 pa-tients with AGC were enrolled as the research objects.According to random number table method,they were divided into the con-trol group(34 cases)and the study group(34 cases).The control group was treated with SOX regimen,while the study group was additionally treated with trastuzumab.The curative effect,serum tumor markers[carbohydrate antigen 724(CA724),carcino-embryonic antigen(CEA),carbohydrate antigen 199(CA199)],immunoglobulins(IgA,IgG,IgM)and incidence of drugs toxic-ity were compared between the 2 groups.Results After treatment,total response rate of the study group was higher than that of the control group(67.65％vs 41.18％,P＜0.05).After treatment,levels of serum CA724,CEA and CA199 in both groups were decreased,which were lower in the study group than the control group(P＜0.05).After treatment,levels of IgA,IgG and IgM in both groups were decreased,which were higher in the study group than the control group(P＜0.05).There was no significant difference in the incidence of drugs toxicity between the 2 groups(P＞0.05).Conclusion Trastuzumab combined with SOX regimen has significant curative effect on AGC patients,which can effectively reduce levels of serum tumor markers and weaken immunosuppressive function,with high application safety.
NETL
NSTL
万方数据
